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Abstract
Aims: Controversy exists in regard to the beneficial effects of transplanting cardiac or somatic progenitor cells upon
myocardial injury. We have therefore investigated the functional short- and long-term consequences after intramyocardial
transplantation of these cell types in a murine lesion model.
Methods and Results: Myocardial infarction (MI) was induced in mice (n = 75), followed by the intramyocardial injection of
1226105 luciferase- and GFP-expressing embryonic cardiomyocytes (eCMs), skeletal myoblasts (SMs), mesenchymal stem
cells (MSCs) or medium into the infarct. Non-treated healthy mice (n = 6) served as controls. Bioluminescence and
fluorescence imaging confirmed the engraftment and survival of the cells up to seven weeks postoperatively. After two
weeks MRI was performed, which showed that infarct volume was significantly decreased by eCMs only (14.862.2%
MI+eCM vs. 26.761.6% MI). Left ventricular dilation was significantly decreased by transplantation of any cell type, but most
efficiently by eCMs. Moreover, eCM treatment increased the ejection fraction and cardiac output significantly to 33.462.2%
and 22.361.2 ml/min. In addition, this cell type exclusively and significantly increased the end-systolic wall thickness in the
infarct center and borders and raised the wall thickening in the infarct borders. Repetitive echocardiography examinations
at later time points confirmed that these beneficial effects were accompanied by better survival rates.
Conclusion: Cellular cardiomyoplasty employing contractile and electrically coupling embryonic cardiomyocytes (eCMs)
into ischemic myocardium provoked significantly smaller infarcts with less adverse remodeling and improved cardiac
function and long-term survival compared to transplantation of somatic cells (SMs and MSCs), thereby proving that a
cardiomyocyte phenotype is important to restore myocardial function.
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Introduction
Myocardial infarction is characterized by extensive necrosis of
cardiomyocytes, which causes a non-reversible loss of rhythmic
contractile abilities [1]. The low proliferative capacity of termi-
nally differentiated cardiomyocytes has led to the exploration of
stem cell-based therapies to regenerate myocardium and reduce
the occurrence of heart failure [2].
Intramyocardial injection of embryonic cardiomyocytes (eCMs)
in mice has previously been shown to result in electrical coupling
to native myocardium, improved ventricular function and
reduction of ventricular arrhythmias [3–6]. The combination of
these key functional characteristics of eCMs is unique compared to
already clinically applied somatic cells such as skeletal myoblasts
(SMs) and mesenchymal stem cells (MSCs). For these cell types
neither electromechanical integration into the heart nor transdif-
ferentiation into cardiomyocytes has been unequivocally proven
[7,8]. Therefore, beneficial effects seen in some animal studies and
human trials after cardiac SM or MSC transplantation [9,10] have
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been preferentially attributed to passive mechanisms such as the
preservation of cardiac compliance or paracrine effects [11].
Nevertheless, this area is still controversial and the best-suited
cell type has not been identified so far. Therefore, the goal of this
study was to investigate in detail global and regional cardiac
contractile function following cellular cardiomyoplasty. In partic-
ular we aimed to address, if observed changes were dependent on
the ability of the cells to contract and couple electrically to native
myocardium. Therefore, contractile and electrically coupling
eCMs were compared to, on the one hand, contractile but not
electrically coupling SMs and, on the other hand, neither
contractile nor electrically coupling MSCs. The cells were
transplanted into infarcted syngeneic hearts of two different
mouse strains (CD1 and C57BL/6).
To evaluate myocardial function, we applied a unique set of
imaging and analysis tools to investigate local and global cardiac
contractile function and geometry, cell survival, and long-term
outcome. High spatial- and temporal-resolution in vivo magnetic
resonance imaging (MRI) was performed to characterize global
cardiac function [12]. Moreover, to investigate active enhance-
ment of local contractility by the transplanted cells throughout the
cardiac cycle, data were evaluated by use of the AHA 16-segment
model, where for each segment 45–50 radial chords were
analyzed. Furthermore, using late gadolinium enhancement
(LGE) MRI, infarcted and remote myocardium could be
discriminated clearly [13]. Additionally, survival of transplanted
cells, cardiac morphology and function were monitored up to 7
weeks by bioluminescence imaging (BLI) and three-dimensional
echocardiography.
Methods
All animal experiments were performed in accordance with the
declaration of Helsinki and were approved by the local ethical
committees for animal experiments of Nordrhein-Westfalen
(LANUV) and the University of Maastricht.
Cell isolation and culture
eCMs and SMs were obtained from transgenic CD-1 and
C57BL/6 mouse embryos, expressing green fluorescent protein
(GFP) under the a-actin promoter as described [4,14,15]. eCMs
were isolated from embryonic hearts at E13.5, whereas for SM
isolation the diaphragm was used at E18.5. Transgenic MSCs
were aspirated from the femur and tibia of adult CD-1 and
C57BL/6 mice, with GFP expression under control of the a-actin
promoter [7].
Viral transduction of cells
Cells underwent lentiviral transduction prior to intracardiac
injection to introduce viral-enhanced firefly luciferase (veff-luc)
expression. Veff-luc was cloned into a pRRL-SIN18 backbone and
its expression was driven by a cytomegalovirus promoter. Four
hours after isolation, cells were incubated at approximately
1.56106 viral particles/2.56105 cells for 10–12 h at 37uC.
Subsequently, cells were washed with phosphate buffered saline
(PBS, Sigma-Aldrich), harvested with trypsin (Gibco) and
resuspended in IMDM-medium at a concentration of 1226105
cells/5 mL.
Myocardial infarction and intramyocardial cell
transplantation
Transmural myocardial infarctions were generated in wild type
male CD-1 (n= 28) and C57BL/6 mice (n = 47) (10–12 weeks old,
Charles River Laboratories, Sulzfeld, Germany). Non-treated
healthy CD-1 mice (n = 6) served as controls. Under general
anesthesia, mice were intubated and mechanically ventilated as
described before [4,14]. The heart was exposed by a left lateral
thoracotomy and the left coronary artery was permanently
occluded directly distal to the left atrial auricle. Thereafter,
1226105 cells or 5 mL IMDM-medium were injected into the
border zones and center of the ischemic area. To visually confirm
intramyocardial delivery, a blue dye was co-injected.
Experimental setup
Two different protocols were used to evaluate the effects of cell
transplantation on cardiac remodeling after myocardial infarction.
1) Short-term effects were studied by MRI 2 weeks after
myocardial infarction in CD-1 mice treated with eCMs
(MI+eCM), SMs (MI+SM), MSCs (MI+MSC) or IMDM-medium
(MI). As a reference, age and gender matched CD-1 mice were
used (no MI). 2) To monitor long-term cell survival and cardiac
remodeling, BLI and/or echocardiography were performed at day
5, 13 and 49 after coronary artery ligation and transplantation of
eCMs, SMs or MSCs (isolated from C57BL/6 mice). For long-
term experiments inbred C57BL/6 mice were used to avoid
rejection of transplanted cells.
In vivo MRI
Cardiac MRI was performed with a 9.4 T scanner (Bruker
Biospin GmbH, Ettlingen, Germany). Mice were anesthetized
with isoflurane and placed in supine position in a 35-mm-diameter
birdcage RF-coil (Rapid Biomedical, Rimpar, Germany). Electro-
cardiogram (ECG), respiration and temperature (Small Animal
Instruments Inc., Stony Brook, USA) were continuously moni-
tored.
Infarct size was assessed by LGE MRI 5 min after intravenous
administration of 0.3 mmol Gd-DTPA/kg bodyweight (Bayer
HealthCare Pharmaceuticals, Mijdrecht, the Netherlands) with an
ECG-triggered and respiratory-gated T1-weighted multi-slice
FLASH sequence in short-axis orientation (TR=63 ms,
TE=1.8 ms, FA= 60u, FOV=363 cm2, matrix = 1926192,
NEX=6, slice thickness = 1 mm, number of slices = 9). For
evaluation of cardiac morphology and function, cine MR-images
in short- and long-axis orientations were acquired with a single-
slice FLASH sequence (TR=7 ms, TE= 1.8 ms, FA= 15u,
FOV=363 cm2, matrix = 1926192, NEX=6, slice thick-
ness = 1 mm). Ten to 11 slices were acquired in short-axis
orientation to cover the heart from apex to base.
MRI data analysis
Epi- and endocardial contours of the left ventricle were traced
semi-automatically [16] in short-axis LGE images and short- and
long-axis cine images in end-diastole (ED) and end-systole (ES)
using CAAS MRV FARM 2.0 software (Pie Medical Imaging,
Maastricht, the Netherlands). To determine the infarct size,
hyperintense voxels within the segmented left ventricle on T1-
weighted LGE MR-images were identified with a threshold
algorithm. The threshold value was defined as the mean signal
intensity within a septal region of interest plus five times its
standard deviation. The transmural infarct volume was calculated
as the volume of infarcted myocardium relative to the total left
ventricular (LV) volume. For quantification of the epicardial
infarct area, the left ventricle was partitioned into 100 segments
per slice. Segments in which infarct transmurality exceeded 50%
were assigned as infarct. The epicardial circumferential length of
the infarcted segments was calculated with home-built software in
Mathematica 6.0 (Wolfram Research Europe, Oxfordshire,
United Kingdom) and was multiplied with the slice thickness to
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obtain the infarct surface area. The epicardial infarct surface area
was calculated as the area of infarcted myocardium relative to the
total LV area.
LV dimensions were described by the endocardial ED and ES
volume (EDV and ESV, respectively) on cine images, which were
also used to calculate global functional parameters as the ejection
fraction (EF) and cardiac output (CO). Regional contractility was
evaluated by applying a three-dimensional centerline model to the
segmented LV [17]. In each short-axis slice 100 radial chords were
calculated that represented the wall thickness (WTS) perpendic-
ular to the myocardial wall. Wall thickening was defined as
WT= (WTSES2WTSED)/WTSES. Regional WTS and WT were
evaluated by distributing all chords according to the standard
American Heart Association (AHA) model [18].
In vivo BLI
Bioluminescence images of luciferase expression were acquired
under isoflurane anesthesia 10 min after intraperitoneal injection
of D-luciferin (25 mg/mouse, AppliChem, Darmstadt, Germany)
with a Xenogen IVIS200 system (Caliper Life Sciences, Hopkin-
ton, USA). Bioluminescence signals were detected for 90 s with a
charge-coupled device camera. Mice transplanted with non-
transduced cells served as control.
In vivo echocardiography
Echocardiography was performed on an HDI-5000 (ATL
Philips Medical Systems, Best, the Netherlands). Mice were
anesthetized with a low-dose of isoflurane and 2D M-mode
images were acquired in short-axis position at 0.5 mm intervals
from apex to base and in long-axis position using a 15 MHz
linear-array transducer allowing frame rates up to 230 Hz. To
calculate functional cardiac parameters, the endocardium was
segmented in ED and ES in both the long-axis image and a single
short-axis image at the level of the papillary muscle.
Ex vivo histology
Mice were sacrificed by cervical dislocation. Hearts were
perfused with PBS, followed by fixation with 4% paraformalde-
hyde (Sigma-Aldrich) and dehydration in 20% sucrose (Sigma-
Aldrich). Short-axis cryosections (10 mm) were prepared at 50 mm
intervals with a CM3050s cryostat (Leica GmbH, Wetzlar,
Germany).
Cell engraftment and differentiation were evaluated ex vivo
using an Axiovert 40CFL fluorescence microscope combined with
an AxioCam MRm camera (Carl Zeiss MicroImaging GmbH,
Go¨ttingen, Germany). To identify engrafted cells and to exclude
autofluorescence, GFP expression was detected with a double filter
(FITC/Cy3), using optimized exposure times.
To assess differentiation, cryosections were fluorescently labeled
with rabbit-anti-mouse connexin43 (1:1000, Peptide Specialty
Laboratories GmbH, Heidelberg, Germany) coupled to donkey-
anti-rabbit DyLight549 (1:400, Jackson ImmunoResearch, Suffolk,
United Kingdom), mouse-anti-human a-actinin (1:400, Sigma-
Aldrich) conjugated to goat-anti-mouse Cy5 (1:400, Jackson
ImmunoResearch) and rat-anti-mouse CD73 (1:400, BD Phar-
mingen. Heidelberg, Germany) combined with goat-anti-rat
Alexa555 (Invitrogen, Darmstadt, Germany). For nuclear staining
Hoechst 33342 (1:1000, Sigma-Aldrich) was used.
Collagen was stained with direct red 80 in picric acid (1 g/L,
both Sigma-Aldrich). Images were acquired with a ProgRes C10
in combination with Capture Pro Image Acquisition Software
(JenOptik Optical Systems GmbH, Jena, Germany) through a
binocular loupe (Leica) with 10 ms shutter time.
Statistical analysis
Data were presented as mean6SEM. One-way analysis of
variance (ANOVA) with Dunnett’s correction for intergroup
comparisons was used to compare MRI data of healthy mice and
eCM-, SM- or MSC-treated mice to untreated mice. One-way
ANOVA with Dunnett’s correction was used to detect differences
between eCM- and SM- or MSC-treated mice. Echocardiography
data were analyzed with repeated measures ANOVA to detect
changes in eCM, SM or MSC transplanted mice. For statistical
analysis of the time-course of survival, a log-rank test was used.
Level of statistical significance was set at a =0.05.
Results
Cell survival and differentiation
Ischemic, necrotic myocardium is a challenging environment
for the engraftment and survival of transplanted cells. Two and 7
weeks after implantation, the presence of grafted cells within the
lesion was proven by their native GFP fluorescence (Figs. 1A and
C). Bright epifluorescence of GFP-expression from eCMs
(MI+eCM), SMs (MI+SM) or MSCs (MI+MSC) was detected in
the infarct. No GFP-fluorescence was observed in infarcted hearts
of mice that did not receive cell injections (MI) and in the
anterolateral LV wall of mice without MI (no MI). The grafted
cells were found exclusively within the infarcted myocardium and
in the border zone of the lesion and did not migrate into remote
myocardium.
The size of the grafts was dependent on the type of cells
transplanted. Similar as reported earlier by our group overall cell
survival was rather poor [4]. To estimate number of engrafted
GFP+ cells we counted the cells and this yielded only a few
thousand in the SM (n=3) and in the eCM grafts (n = 3) [4]. For
MSC only singular engrafted cells were detected (Fig. 1A). One
mouse in which cell engraftment had failed was excluded from
further analysis. Mice with successful engraftment of eCMs (n= 5),
SMs (n= 7) and MSCs (n= 7) were included.
In Fig. 1B, picrosirius histological staining illustrates the effect of
cell transplantation on the architecture of the left ventricle 2 weeks
postoperatively. Compared to wild-type mice (no MI), LV dilation
and wall thinning at the lesion site were most prominent in mice
with myocardial infarction that were not treated (MI). After
intramyocardial injection of SMs (MI+SM) or MSCs (MI+MSC)
only a slight reduction of LV dilation was observed. After
transplantation of eCMs (MI+eCM) dilation of the left ventricle
was clearly more attenuated compared to the other groups.
Furthermore, LV wall thickness within the infarct was increased
by the engraftment of eCMs, which like the SMs could be
identified within the lesion by picrosirius red staining as islets of
viable cells.
In transplanted eCMs the gap junction protein Connexin43 as
well as a-actinin expression could be demonstrated 2 and 7 weeks
postoperatively. Data at 7 weeks are presented in Fig. 1C.
Engrafted cardiomyocytes showed prominent cross-striation indi-
cating further differentiation of the transplanted eCMs [4]. As
expected, grafted SMs only stained positive for a-actinin, but not
for Connexin43, indicating their differentiation into mature
myocytes. MSCs did not adopt a contractile phenotype and,
moreover, still expressed the MSC-marker CD73 [7].
Infarct volume and area
Histology established differences in cell engraftment and
survival, as well as changes in infarct remodeling. In order to
quantify the impact on cardiac function in vivo, high-resolution
MRI scans were performed 2 weeks post-operatively. Represen-
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tative LGE short-axis MR-images for the various groups are
shown in Fig. 2A. These images were obtained at the mid-LV
level, making them therefore very comparable. The hyperen-
hanced infarcted myocardium could clearly be delineated in mice
with MI, MI+SM and MI+MSC, whereas in mice with MI+eCM
an inhomogeneous pattern of epicardial signal enhancement was
observed in the anterolateral wall.
Quantification of the relative transmural infarct volume (Fig. 2B)
indicated that transplantation of eCMs after myocardial infarction
led to a significant decline in the infarct volume from 26.761.6%
(MI, n= 8) to 14.862.2% (MI+eCM, n= 5). This was a unique
feature of eCM therapy, since intramyocardial injection of SMs
(n = 5) or MSCs (n = 7) had no significant effect on the infarct
volume (25.362.1% and 25.962.3%, respectively, p.0.05 vs.
MI). Another common measure of chronic infarct size is the
epicardial surface area of LV segments consisting of more than
50% infarcted myocardium (Fig. 2C). The relative infarct area
showed a similar trend as the infarct volume (compare Figs. 2B
and C). The relative epicardial infarct area was significantly
reduced by eCM treatment from 31.762.1% (MI) to 15.261.9%
(MI+eCM, p,0.05), but no significant changes were found in case
of SM or MSC injection (28.562.5% and 30.263.2%, respec-
tively). Furthermore, when comparing the effect of transplantation
of eCMs to that of SMs and MSCs, the infarct volume and area
were both significantly lowered by eCM engraftment (p,0.05,
MI+eCM vs. MI+SM and MI+MSC).
Global cardiac morphology and function
The effect of cell transplantation on various aspects of cardiac
remodeling was evaluated two weeks after myocardial infarction
with in vivo cine MRI. In Figs. 3A and B a collection of
representative short- and long-axis end-diastolic cardiac MR-
images is shown for the five groups. A decrease in LV dilation was
observed by transplantation of either type of cells, which was in
accordance with ex vivo histology (Fig. 1B).
Quantitative analysis of LV dimensions showed that both EDV
(Fig. 3C) and ESV (Fig. 3D) were significantly decreased by
transplantation of any of the three different cell types (p,0.05 vs.
MI). Cell therapy caused a decrease in EDV from 214.1614.6 mL
(MI, n= 8) to 121.667.6 mL (MI+eCM, n= 5), 163.6617.3 mL
(MI+SM, n= 7) and 160.567.2 mL (MI+MSC, n= 7), whereas
ESV decreased from 184.7616.3 mL (MI) to 81.366.7 mL
(MI+eCM), 133.3617.4 mL (MI+SM) and 123.967.9 mL
(MI+MSC). Importantly, the attenuation of LV dilation was most
prominent when mice received eCMs (MI+eCM vs. MI+SM,
p,0.05, and MI+eCM vs. MI+MSC, p,0.1).
An improvement of EF (Fig. 3E) after transplantation of all
three cell types (MI+eCM 33.462.2%, MI+MSC 23.261.6%,
MI+SM 19.763.1%) compared to MI mice (14.962.4%) could be
Figure 1. Fluorescence microscopy and histology of myocardial tissues of treatment and control groups. A) Ex vivo fluorescence
microscopy of GFP expressing eCMs, SMs and MSCs two weeks after transplantation in infarcted myocardium to evaluate cell engraftment and
survival. GFP is depicted in green and autofluorescence is shown in red. Scale bar = 20 mm. B) Ex vivo picrosirius red staining to determine general
infarct composition two weeks postoperatively. Engrafted eCMs and SMs can be identified within the lesion (arrows). Scale bar = 1 mm. C) Ex vivo
fluorescence microscopy to evaluate cell differentiation at 7 weeks (no MI, MI+eCM, MI+SM, MI) or 2 weeks (MI+MSC) after surgery and
transplantation. For all groups, GFP fluorescence is depicted in green and cell nuclei in blue. For eCM (top) and SM (middle) the cardiomyocyte
marker Connexin43 is shown in red and a-actinin in white, whereas for MSC (bottom) the mesenchymal stem cell marker CD73 is shown in red. Scale
bars = 20 mm.
doi:10.1371/journal.pone.0061510.g001
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demonstrated, which reached a significant level (p,0.05) for eCM
and MSC groups. Within the cell transplantation groups again the
increase of EF was significantly higher (p,0.05) after intramyo-
cardial injection of eCMs compared to MSCs or SMs. The eCM
therapy significantly restored CO (Fig. 3F) from 15.860.9 mL/
min (MI) to 22.361.2 mL/min (MI+eCM). Importantly this value
reached almost that of the wild type mice (21.660.5 mL/min).
CO was not or only barely improved in mice that received SMs or
MSCs (14.661.6 mL/min and 18.661.2 mL/min, respectively,
p.0.05 vs. MI).
In summary, our morphological and functional analysis
demonstrated that cell therapy with any of the three different
cell types used could attenuate post-infarct ventricular dilatation.
However, the positive effects were much more pronounced after
intramyocardial eCM injection. Extensive functional MRI analysis
also yielded impressive improvements in the eCM group and are
therefore fully in line with the above reported histological findings.
Regional myocardial contractility
In vivo MRI proved that eCMs, but not autologous stem cell
treatment, significantly attenuates infarct size and significantly
improves global function. To elucidate whether cellular cardio-
myoplasty could also improve regional contractile function,
changes in local LV wall thickness were studied throughout the
cardiac cycle by exploiting the high contrast on in vivo cine MR-
images between the myocardium and surrounding tissue.
Figures 4A and B illustrate the mean regional end-systolic wall
thickness (WTSES) and wall thickening (WT) two weeks postop-
eratively in 16 segments of the standard AHA model. Both WTSES
and WT were reduced by myocardial infarction at the apical and
mid-LV level (p,0.05 no MI vs. MI).
Transplantation of eCMs resulted in a significant increase in the
WTSES in all apical and mid-LV segments, except for the apical
anterior segment (AHA segment #13) (Fig. 4A). In the apex, the
mean WTSES of all segments (#13–16) increased from
447633 mm (MI) to 628654 mm (MI+eCM), whereas at the
mid-LV level eCM treatment improved the mean WTSES of all
segments (#7–12) from 650692 mm (MI) to 970694 mm
(MI+eCM).
Moreover, eCM injection enhanced the WT at the apical as
well as mid-LV level (Fig. 4B). In the apex, the mean WT (#13–
16) increased from 23.862.3% (MI) to 4.663.9% by eCM
transplantation (p,0.05). Furthermore, there was a significant
(p,0.05) augmentation in the WT of the inferior segment (#15)
from 23.162.1% (MI) to 13.164.7% (MI+eCM). At the middle
of the left ventricle in the infarct border zone, WT was significantly
enhanced by eCM transplantation in the anteroseptal (#8),
inferoseptal (#9), inferior (#10) and inferolateral (#11) segments
(p,0.05 vs. MI). Furthermore, in the anterior area (#7) a trend
towards improved WT was found by eCM therapy (p = 0.07 vs.
MI). The mean WT at the mid-LV level (#7–12) was increased
from 2.565.1% (MI) to 20.368.0% (MI+eCM) (p,0.05). No
significant improvements in WT were detected at the approximate
site of eCM delivery (anterolateral segments #12, 13 and 16).
For SM and MSC transplantation no evident improvements in
both WTSES and WT were observed. Therefore, eCMs had the
unique potential to improve local myocardial contractile function,
especially within the border zones at the mid-LV level.
Long-term effects of cell engraftment to animal survival
and cardiac function
The MRI analysis clearly proved a prominent functional benefit
by the engraftment of eCMs. However, earlier studies suggested
that such beneficial effects of cell replacement could be of transient
nature [19]. For this, long-term effects of cell engraftment to
animal survival and cardiac function were studied in a second
series of mice up to 7 weeks postoperatively. We specifically
compared eCMS to SMs and MSCs, because for the latter two
cardiac function was significantly less augmented. In Fig. 5A,
survival curves of treated mice clearly illustrate that long-term
survival was dependent on the type of injected cells. Transplan-
tation of eCMs significantly improved the survival of mice with
myocardial infarction compared to MSCs (p,0.05). Seven weeks
after cell transplantation, 65% (n= 11/17) of the mice that
Figure 2. Quantification of infarct size by MRI. A) Representative in vivo T1-weighted mid-LV short-axis LGE MR-images two weeks after
myocardial infarction for each experimental group. Infarct size was quantified from LGE images as B) relative transmural infarct volume and C) relative
epicardial infarct surface area. No MI: n = 6, MI+eCM: n = 5, MI+SM: n= 5, MI+MSC: n = 7 and MI: n = 8. * = p,0.05 vs. MI, { = p,0.05 vs. MI+eCM. The
infarct volume and area measured in wild type mice (no MI) was indicative for the accuracy of the analysis.
doi:10.1371/journal.pone.0061510.g002
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received eCMs completed the entire protocol, as opposed to 50%
(n= 7/14) and 0% (n= 0/16) of the mice with SM and MSC
transplantation, respectively. Especially, the low survival of MSC
mice could be explained by the poor cell engraftment and the
commonly observed high mortality in this permanent occlusion
infarction model by extensive adverse remodeling [1,20]. Most of
the MSC mice showed clinical signs of heart failure, namely
increasing shortness of breath due to pulmonary congestion prior
to death. These observations are in line with our MRI data, were
MSC mice showed the biggest infarcts.
Long-term cell engraftment was monitored by in vivo BLI of
luciferase expression by viable transplanted cells. Signals originat-
ing from engrafted eCMs, SMs and MSCs at 5, 13 and 49 days
after intramyocardial transplantation were detected (Fig. 5B).
Over time, a slight signal decrease was observed for all three cell
types, related to a loss of transplanted cells from the myocardium.
In some hearts we have performed detailed quantitation of
engrafted cells. Our analysis yielded for eCMs (n= 3) and SMs
(n= 3) less than 5000 cells, thereby confirming their long-term
survival, but also their steady decline in number and this is fully in
accordance with the decrease in the bioluminescent signal (Fig. 5B).
The progression of cardiac remodeling after cell transplantation
was followed with in vivo echocardiography up to seven weeks
postoperatively. Figure 5C shows the EF, the akinetic area (as a
measure for infarct size), stroke volume, and EDV at day 5 and 49.
Functional parameters at day 5 were essentially the same between
the groups, indicating that initial infarct size and cardiac function
between groups were comparable. At day 49, heart function of
mice treated with eCMs tended to be better than those treated
with SMs (higher EF and larger stroke volume), although
differences did not reach statistical significance; this may be also
due to the fact that mice with SM and bad LV function had
Figure 3. Quantification of cardiac function by MRI. Representative in vivo end-diastolic MR-images two weeks after myocardial infarction in A)
short-axis (mid-LV) and B) long-axis orientation for each experimental group. Global cardiac morphology and function were obtained from in vivo
cine MR-images: C) EDV, D) ESV, E) EF and F) CO. No MI: n = 6, MI+eCM: n = 5, MI+SM: n= 7, MI+MSC: n= 7 and MI: n = 8. * = p,0.05 vs. MI, { =
p,0.05 vs. MI+eCM.
doi:10.1371/journal.pone.0061510.g003
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Figure 4. Assessment of regional contractile function by MRI. Regional contractile function two weeks after myocardial infarction, described
by group-averaged A) end-systolic wall thickness and B) wall thickening after segmentation of the LV according to the 16 segment AHA model for
mice with no MI (n = 6), MI+eCM (n = 5), MI+SM (n = 7), MI+MSC (n= 7) and MI (n = 8). * = p,0.05 vs. MI, { = p,0.1 vs. MI. The segment numbering is
clarified in A).
doi:10.1371/journal.pone.0061510.g004
Figure 5. Long-term cell survival and treatment outcome. A) Survival curves of mice with myocardial infarction transplanted with eCMs
(n = 17), SMs (n = 14) and MSCs (n = 16), followed 7 weeks postoperatively. B) In vivo longitudinal BLI of representative mice at 5, 13 and 49 days after
transplantation of eCMs (top) SMs (middle) and MSCs (bottom) to monitor long-term cell survival in infarcted myocardium. C) Longitudinal evaluation
of heart function with echocardiography at day 5 and 49 after transplantation of eCMs, SMs and MSCs.
doi:10.1371/journal.pone.0061510.g005
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already died. These long-term echocardiographic data were in line
with the MRI results two weeks postoperatively, since at this time
point eCM-treated mice showed better LV function, which
resulted in better survival numbers. Nevertheless, we could also
observe a deterioration of LV function in eCM, this is consistent
with earlier reports [21] and may be also related to a steady loss of
grafted cells.
Discussion
Transplantation of eCMs, SMs or MSCs in infarcted myocar-
dium led to the following observations: 1) only eCM transplan-
tation reduced the relative infarct size. 2) LV dilation was
attenuated by any type of cell therapy, as reflected in decreased
EDV and ESV, though most by eCMs. 3) eCM transplantation
resulted in the largest improvement in global contractile function.
4) As hypothesized, local contractile function was only improved
by eCMs. However, this effect was restricted to the infarct border
zones. 5) Long-term follow-up showed a superior survival of eCM-
treated mice compared to SMs and MSCs.
The ability of embryonic and autologous stem cells to improve
the architecture of infarcted myocardium has been extensively
explored [2]. However, somatic stem cells often fail to regenerate
functional myocardium and contribute only through passive
mechanisms to cardiac remodeling [22,23]. Embryonic cardio-
myocytes or stem cell derived cardiomyocytes that integrate
electromechanically with native myocardium could provide the
heart with new rhythmically contractile units [4,19,24,25].
To study this topic, syngeneic GFP expressing murine
embryonic cardiomyocytes (eCMs), or also clinically used somatic
stem cells, namely SMs or bone-marrow-derived MSCs, were
injected intramyocardially into infarcts. SMs and MSCs were not
expected to differentiate into cardiomyocytes, but were able to
form contractile myotubes or mesenchymal cells like fibroblasts,
osteoblasts or lipocytes, respectively [2,7,8].
An in vivo multimodal imaging approach was used combining
BLI to evaluate cell survival, and MRI and echocardiography to
determine the effect of eCMs, SMs and MSCs on cardiac
remodeling. Repetitive BLI of luciferase expression by the
transplanted cells showed survival of eCMs and SMs up to seven
weeks postoperatively (Fig. 5B). SMs were found to engraft better
compared to the other cell types used and also to eCM (Fig. 5B).
This is a consistent finding also in our earlier studies and probably
can be related to the bigger size of the SMs. Dissociated eCMs are
more or less round shaped and 20–30 mm in diameter. SMs are
fusiform 20–30 mm in diameter and up to 200 mm long. Also SMs
are better resistance to hypoxic conditions within the infarcted
area. As shown before despite better initial engraftment of SM,
eCM transplantation results, also short term, in better hemody-
namic augmentation [4].
In time, a gradual loss of cells from the heart was observed with
BLI, but functional benefits seen after two weeks were still detected
seven weeks postoperatively [22,23,26,27]. BLI has a high
sensitivity to detect luciferase-expressing cells and was preferred
over physical labeling of cells with MR-contrast agents such as iron
oxides. Iron oxide labeling cannot report on cell viability and
importantly several studies have observed MR hypoenhancement
originating from leukocytes that phagocytized dead iron-laden
cells [28–30]. Additionally, iron oxide disturbs the anterolateral
myocardial contrast required for segmentation of the epi- and
endocardium and interferes with LGE evaluation of infarct size
[31]. MRI enabled detailed analysis of cardiac function and
remodeling, because of its superior ability to visualize the endo-
and epicardium compared to other imaging modalities [32–34].
Many studies have observed positive effects of cell therapies on
global cardiac parameters [4,11,19,22,25,26,35–37]. It was
hypothesized by Wall et al. that this could be attributed to a
reduction in wall stress by the intramyocardial presence of
compliant material [38]. Indeed, LV remodeling was significantly
impaired by transplantation of all three cell types. For SMs and
MSCs this was also observed, at least transiently, in clinical studies.
However, this effect was most prominent in the eCM group
(Figs. 3C–D), which indicates that the progression of cardiac
remodeling also depended on cardiomyocyte-related cell features.
This was supported by the finding that the volume fraction of
chronically infarcted myocardium was only affected by eCM
therapy (Figs. 2B–C). Importantly, this finding was not related to
cell graft size, since approximately equal numbers were counted in
eCM and SM transplanted hearts [39]. In addition, the
endocardial areas of MR-signal hypointensities detected after
eCM transplantation, which were absent after both SM and MSC
therapy, do not correspond to regions of enhanced survival of
native cells in the infarct as transmural infarcts were observed in all
mice.
A plausible explanation for the smaller infarct size could be that
eCMs prevented infarct expansion into the viable border zones. In
the acute phase of myocardial infarction, infarct expansion is
caused by cardiomyocyte slippage, which results in infarct wall
thinning and dilation [40]. The alignment and electrical integra-
tion of eCMs with the native myocardium for synchronized
contraction could limit sliding of cardiomyocyte bundles and
might actively preserve local wall shear stress, which reduces
systolic bulging and thus acute infarct expansion. In earlier studies,
we and others have provided evidence that engrafted eCMs and
human ES cell cardiomyocytes can couple electrically with the
native myocardium, using genetic Ca2+ sensors combined with cell
grafting experiments [4,41]. This might prevent chronic progres-
sive infarct extension into viable border zones, which is caused by
stretch-induced myocyte apoptosis in areas that experience
increased wall shear stress [42]. Thereby, transplantation of cells
with a cardiomyocyte phenotype in infarcted myocardium might
rescue the neighboring non-ischemic myocardium. This would
also explain why eCM therapy showed most potential to maintain
LV morphology and function (Figs. 3C–F).
Analysis of the local contribution of eCMs to the infarct and its
border zones indeed showed that infarct wall thinning was less
prominent after eCM therapy (Fig. 4A). However, the transplan-
tation of contractile eCMs was not sufficient to restore wall
thickening in the anterolateral infarct center (Fig. 4B). This is
probably related to the relatively low survival of intramyocardial-
injected eCMs in total and especially in the center of the lesion.
Cells preferentially engrafted close to and within the less ischemic
and still perfused infarct border zones. As shown in Fig. 4, WTSES
and WT were significantly increased in these segments compared
to non-treated hearts. To our opinion different mechanisms
contribute to this phenomenon. Implanted eCMs act anti-
apoptotic resulting in smaller infarct sizes, stimulate proliferation
(proven by Ki67 stainings, data not shown), and augment the
extracellular matrix as demonstrated for the extracellular matrix
protein perlecan before resulting is less dilation [43]. After
integration into the host tissue eCMs are able to couple
electrically. Since engraftment predominantly happens within the
border zone it is difficult to distinguish between active and passive
effects. Nevertheless in the past force generation of transplanted
murine eCMs within myocardial scar tissue was shown [3].
Whether primarily secretion of factors or proteins also of the co-
transplanted cardiac fibroblasts, or also the ability to form cell-cell
contacts to the host tissue plays a major role has to be cleared in
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future studies. Nevertheless, the combination of local effects on the
lesion and global effects to the remaining LV myocardium resulted
in significantly better hemodynamic performance of eCM treated
hearts as depicted in Figs. 3E and F. These results clearly
emphasize the necessity of a rhythmically contractile cell
phenotype for cell replacement strategies in the infarcted as was
previously suggested by Sakai et al. [11].
Long-term monitoring of cardiac function by echocardiography
provided two major findings: Survival of the three populations was
quite different (Fig. 5A). Most survivors were seen in the eCM
group, while all MSC injected mice died during the first five
weeks. Half of deaths after SM transplantation occurred during
the first postoperative week. This is interesting as in clinical studies
ventricular tachycardia (VT) were observed after SM transplan-
tation and we could prove in the past increased malignant VT
incidence during electrophysiological testing after SM transplan-
tation in a murine infarct model [4,44]. Furthermore, SM and
MSC treated mice showed severely impaired LV geometry on
MR-images. While survival of eCMs and SMs could still be
demonstrated by BLI and histology seven weeks postoperatively
(Fig. 5B), bone marrow derived cells were nearly absent four weeks
postoperatively in previous studies [45]. With echo, clear
differences of EF were seen in eCM and SM treated mice.
Various other groups have also evaluated the long-term contribu-
tion of cell transplantation to cardiac function after myocardial
infarction [19,22,23,25–27,30,35]. Van der Bogt et al. reported
improved contraction by SM therapy, but not by MSCs [22,23].
Van Laake et al. observed non-persistent improvements in global
function after transplantation of human embryonic stem cell-
derived cardiomyocytes (ESC-CM) during a 12 week follow-up
[19]. These conflicting results with the current study might be
ascribed to differences in the origin of the cells used (adult vs. fetal,
human vs. murine).
The importance of a cardiomyocyte cell phenotype for
successful recovery of local contractile function is supported by a
recent study by Qiao et al. [25]. They reported long-term
improvements after two months in regional contractility of
ischemia-reperfusion injured myocardium by ESC-CM therapy
in rats. In analogy with our results, coupling of ESC-CMs by
Connexin43 expression to native cardiomyocytes was observed
and this electromechanical integration was probably responsible
for improved infarct contractility.
The present study has some limitations. The mouse model of
myocardial infarction by permanent ligation of the LAD has a
given higher mortality than after e.g. cryolesion injury. This led,
especially in the long-term experiments, to smaller group sizes. On
the other hand, coronary ligation represents a more relevant
physiological model of myocardial infarction. Also, individual
anatomical variations of the coronary system in the mouse may
result in significant variations in infarct size. We have therefore
determined infarct size by echocardiography in all long-term
experiments at 5 days after the infarction and injection of cells.
These scans revealed no significant differences in the infarct size
between the groups.
To conclude, this study provided convincing evidence that
eCMs improved local and global contractile function after
myocardial infarction. This drastically altered the course of global
cardiac remodeling and prevented progressive infarct expansion
into neighboring non-ischemic myocardium, which ultimately
improved long-term survival. These effects were probably caused
by the ability of eCMs to develop into contractile cardiomyocytes
and form gap junctions and were therefore exclusively associated
with eCM, but not SM or MSC therapy after myocardial
infarction.
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